Potential treatment for allergic disease including severe steroid resistant asthma


A novel approach shows promising results as a potential therapeutic for allergic conditions, including severe steroid resistant asthma. A peptide has been identified, HpARI, that inactivates and inhibits release of IL-33 a critical step in the development of allergic disease.

Bile duct cancer is difficult to detect

APPLICATION

  • Therapy for severe, steroid-resistant asthma therapy and other IL-33 mediated allergic disease

DEVELOPMENT STATUS

Proof of concept

IP STATUS

UK priority filing

COMMERCIAL OFFERING

  • Collaborative research

OPPORTUNITY


Severe steroid resistant asthma is an allergic disease that affects around 5% of asthmatics, but requires 50% of the total NHS spend to treat. There are no treatments and it is considered as a major unmet need.

IL-33 cytokine release has been shown to be a critical step in a range of allergic diseases, and high IL-33 levels in the lung have been associated with severe asthmatic pathology. IL-33 has been proposed as a potential target for steroid-resistant asthma. Candidates that directly block released IL-33 are in development, but none of these prevent the release of IL-33 from necrotic cells or selectively bind only the active form of IL-33, which is required for therapeutic effect.

TECHNOLOGY


Our technology, HpARI, centres around a peptide derived from the secretions of a helminth parasite, and which we have shown blocks the release of IL-33 from cells, and binds to active IL-33 only. This dual strategy is a potentially more efficacious and efficient approach to treatment than current candidates.

HpARI suppresses allergic immune responses, lung pathology, and improves lung function through interference in the IL-33 pathway in in vivo and in vitro models. We have characterised the domains and binding sites necessary for activity, and the design of drugable peptides is currently underway.

BENEFITS


  • A previously unknown mechanism to modulate IL-33
  • More efficient approach than binding active and inactive form of IL-33; lower concentration required for effect
  • Dual strategy differs from other anti-IL33 candidates
  • Current tools are ineffective in detection and blockade of active IL-33

 

PUBLICATION


Osbourn et al., (2017). Immunity. 47 (4): 739-751.

Enquiry for: Potential treatment for allergic disease including severe steroid resistant asthma

7 + 7 =

CONTACT US

1-7 Roxburgh Street

Edinburgh EH8 9TA

0131 650 9090

SITEMAP

Home                           About Us    

For Business               News and Events  

For Staff       

For Students

 

 

SIGN UP TO OUR NEWSLETTER

Join our conversation and stay up-to-date with the latest innovations, news and upcoming events

News

10 + 4 =

 
Contact Us | Freedom of Information | Cookie Policy | Privacy Statement | Terms and Conditions | Modern Slavery Act